RxDoctor Payments DataLook up a doctor →

Suzanne Kovacs, MD

Internal Medicine · Spartanburg, SCNPI 1730133646

Payments from drug & device makers

$14,073in general payments, 2019–2025

Across 934 payments — averaging $15.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Pfizer$2K
  • Amgen$1K
  • AstraZeneca$910
  • Astellas Pharma US Inc$672
  • Lilly USA, LLC$497
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$13,80398%
  • Education$2692%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)174$2,197
Pfizer103$1,511
Amgen(2 entities)94$1,255
AstraZeneca60$910
Astellas Pharma US Inc26$672
Lilly USA, LLC33$497
Novartis28$492
Boehringer Ingelheim29$436
Novo Nordisk37$428
GSK26$380
Amarin Pharma, Inc.26$366
Neurocrine Biosciences, Inc.20$342
Bayer18$289
Takeda Pharmaceuticals U.S.A., Inc.17$261
Merck15$261
Kowa Pharmaceuticals America, Inc.20$255
Dexcom, Inc.14$245
Sumitomo Pharma America, Inc.12$242
Sanofi-aventis U.S. LLC15$233
Eisai Inc.15$198
Biohaven Pharmaceutical Holding Company Ltd.11$196
Abbott9$183
Johnson & Johnson15$169
Daiichi Sankyo Inc.9$164
Esperion Therapeutics, Inc.9$149
Medtronic(2 entities)8$142
Biohaven Pharmaceuticals, Inc.7$111
Supernus Pharmaceuticals, Inc.5$109
Upsher-smith Laboratories LLC7$105
Exact Sciences6$105
Otsuka America Pharmaceutical, Inc.3$71
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC4$69
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$65
Shield Therapeutics Inc4$65
Antares Pharma, Inc.3$53
Phathom Pharmaceuticals, Inc.3$52
Ironwood Pharmaceuticals, Inc3$50
IBSA Pharma Inc.3$48
Edwards Lifesciences2$47
Acadia Pharmaceuticals Inc3$45
Philips North America LLC3$44
Verona Pharma, Inc.2$38
Axsome Therapeutics, Inc.2$38
E.r. Squibb & Sons, L.L.C.2$38
Lundbeck LLC2$37
Genentech USA, Inc.2$32
Xeris Pharmaceuticals, Inc.2$30
Bausch Health US, LLC2$28
Vifor Pharma, Inc.1$26
Recor Medical Inc1$25
Inari Medical, Inc.1$22
Gilead1$21
Tolmar, Inc.1$20
Ascensia Diabetes Care US Inc.1$19
Nabriva Therapeutics, PLC1$18
Impel Pharmaceuticals Inc.1$18
Scilex Pharmaceuticals Inc.1$18
Vyera Pharmaceuticals, LLC1$17
Boston Scientific1$17
Scpharmaceuticals Inc.1$16

How this compares

$14,073 in reported general payments places this provider in the 95th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$400,802
Medicare patients
605
Services billed
17,799

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide175$212,465
OzempicSemaglutide189$207,140
EliquisApixaban208$189,843
JardianceEmpagliflozin137$152,532
FarxigaDapagliflozin Propanediol92$90,045
Repatha SureclickEvolocumab101$81,710
LinzessLinaclotide59$76,152
XareltoRivaroxaban58$50,588
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog23$35,506
JanuviaSitagliptin Phosphate23$32,281
MyrbetriqMirabegron34$29,865
TrulicityDulaglutide18$28,698
RybelsusSemaglutide17$28,175
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$26,495
Tresiba Flextouch U-200Insulin Degludec24$23,682

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$497$241,162193 claims
Novo NordiskOzempic, Rybelsus$428$235,315206 claims
PfizerEliquis, Premarin$1,511$203,944249 claims
Boehringer IngelheimJardiance, Glyxambi$436$160,241150 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$910$109,328130 claims
AbbVieLinzess, Synthroid$2,197$87,056183 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$380$52,43882 claims
Johnson & JohnsonXarelto$169$50,58858 claims
MerckJanuvia$261$32,28123 claims
Astellas Pharma US IncMyrbetriq$672$29,86534 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Dexilant$261$25,04322 claims
NovartisEntresto$492$12,86011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Spartanburg

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →